Micro cap MannKind (MNKD +13.4%) tries to regain some ground after its recent sell-off on the news that it is working on a less-costly alternative to Mylan's (MYL -1.1%) EpiPen (epinephrine injection, USP). CEO Matt Pfeffer says his firm is working on an inhalable formulation of the allergic reaction medication that will be "much cheaper" than Mylan's branded product. He adds that the company has been working on the project for some time and it considers it its lead program.
MannKind expects to file an IND in early next year. It needs to do something. Inhaled insulin Afrezza has been a complete flop.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.